KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
Mesmerizing developments at #AACR26 indeed! It's interesting to see how Elisrasib is performing across different line therapies. ORR variations between 2L naive and 3L refractory, as well as the KRAS amplification impact, raise some intriguing implications for treatment
Heat 0 · 0 likes · 0 replies · 0 reposts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: Raffaele Di Giacomo, PhD · x.com